Abstract
Over the last decades, there has been an increasing need to discover new diagnostic RA biomarkers, other than the current serologic biomarkers, which can assist early diagnosis and response to treatment. The purpose of this study was to analyze the serum peptidomic profile in patients with rheumatoid arthritis (RA) by using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). The study included 35 patients with rheumatoid arthritis (RA), 35 patients with primary osteoarthritis (OA) as the disease control (DC), and 35 healthy controls (HC). All participants were subjected to serum peptidomic profile analysis using magnetic bead (MB) separation (MALDI-TOF-MS). The trial showed 113 peaks that discriminated RA from OA and 101 peaks that discriminated RA from HC. Moreover, 95 peaks were identified and discriminated OA from HC; 38 were significant (p < 0.05) and 57 nonsignificant. The genetic algorithm (GA) model showed the best sensitivity and specificity in the three trials (RA versus HC, OA versus HC, and RA versus OA). The present data suggested that the peptidomic pattern is of value for differentiating individuals with RA from OA and healthy controls. We concluded that MALDI-TOF-MS combined with MB is an effective technique to identify novel serum protein biomarkers related to RA.
Highlights
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis that results in the destruction of articular cartilage and bone erosion [1]
Immunological studies revealed the presence of specific serological markers such as anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) that aid in the diagnosis of rheumatoid arthritis (RA) [2]
Osteoarthritis patients were selected with primary OA of knee joints without any underlying cause of secondary OA and were classified by a five-grade scale according to the Kellgren and Lawrence (KL) radiographic classification scheme [13]
Summary
Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis that results in the destruction of articular cartilage and bone erosion [1]. Immunological studies revealed the presence of specific serological markers such as anti-cyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) that aid in the diagnosis of RA [2]. The diagnosis is usually easy in established stages of the disease when the lesions are clinically and radiologically apparent. League Against Rheumatism (ACR/EULAR) classification criteria [4] for RA have been focused on features at earlier stages of disease rather than defining the disease by its late-stage manifestations. This will reinforce attention on the urgent need for earlier diagnosis to prevent, or at least decrease, the occurrence of the undesirable sequelae of RA
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
